TRCT
AARD

Tower Research Capital (TRC)’s Aardvark Therapeutics AARD Stock Holding History

Tower Research Capital (TRC)’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.6K Buy
5,467
+4,656
+574% +$48.3K ﹤0.01% 3459
2025
Q4 		$10.6K Sell
811
-374
-32% -$4.67K ﹤0.01% 3729
2025
Q3 		$15.7K Sell
1,185
-83
-7% -$936 ﹤0.01% 3524
2025
Q2 		$17.1K Buy
+1,268
New +$13.1K ﹤0.01% 3757

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Tower Research Capital (TRC)'s AARD Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Aardvark Therapeutics (AARD) stake by 574% in Q1 2026, buying an estimated $48.3K and bringing the position to 5,467 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3459.

Tower Research Capital (TRC) first reported a position in AARD in Q2 2025 and has held it in 4 quarters since. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Tower Research Capital (TRC) held 5,467 shares of Aardvark Therapeutics worth $20.6K as of Q1 2026.
  • Tower Research Capital (TRC) bought 4,656 Aardvark Therapeutics shares in Q1 2026, an estimated $48.3K.
  • Aardvark Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3459 holding.
  • Tower Research Capital (TRC) first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.